This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Orkin, S.H. J. Biol. Chem. 252, 5606–5608 (1977).
Wortzman, M.S. & Baker, R.F. Biochim. Biophys. Acta 609, 84–96 (1980).
Rosenberg, U.B. et al. Nature 313, 703–706 (1985).
Harland, R. & Weintraub, H. J. Cell. Biol. 101 , 1094–0199 (1985).
Li, Y.X. et al. Virology 255, 138–149 ( 1999).
Naka, K. et al. Biochem. Biophys. Res. Commun. 255, 753– 758 (1999).
Monteith, D.K. et al. Toxicol. Sci. 46, 365–374 (1998).
Nielsen, P.E. Curr. Opin. Biotechnol. 10, 71–75 (1999).
Flechsler, I. et al. Adv. Exp. Med. Biol. 451, 469– 472 (1998).
Im, S.A. et al. Cancer Res. 59, 895–900 (1999).
Desai, R.P. & Papoutsakis, E.T. Appl. Environ. Microbiol. 65, 936–945 ( 1999).
Crooke, S.T. & Bennett, F.C. Ann. Rev. Pharmacol. Toxicol. 36, 107–129 ( 1996).
Good, L. & Nielsen, P.E. Nat. Biotechnol. 16 , 355–358 (1998).
Ecker, D.J. & Freier, S.M. Nat. Biotechnol. 16 , 332 (1998).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Persidis, A. Antisense therapeutics. Nat Biotechnol 17, 403–404 (1999). https://doi.org/10.1038/7973
Issue Date:
DOI: https://doi.org/10.1038/7973
This article is cited by
-
Silencing human genetic diseases with oligonucleotide-based therapies
Human Genetics (2013)
-
Antisense cancer therapy: The state of the science
Current Oncology Reports (2000)